Neuroinflammation and immune regulation in ischemic stroke: Identification of new pharmacological targets

Neuroinflammation and Neurodegeneration

Volumn , Issue , 2014, Pages 199-244

  Di Napoli, Mario ^a,b,c   Smith, Craig J ^d   Hopkins, Stephen J ^d   Popa Wagner, Aurel ^e   Buga, Ana Maria ^e,f   Slevin, Mark ^g,h  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b Neurological Section   (Italy)

^c VICTORIA INFIRMARY   (United Kingdom)

^d SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^e Electron Microscopy Center University Medicine   (Germany)

^f UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^g MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adaptive immunity; C Reactive protein; Cerebral ischemia; Danger associated molecular pattern molecules (DAMPs); Hypothermia; Innate immunity; Neuroinflammation

Indexed keywords

EID: 84929859709     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-1071-7_11     Document Type: Chapter

References (254)

1. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol. 2009;8:345-54.
2. Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, et al. Stroke: working toward a prioritized world agenda. Stroke. 2010;41:1084-99.
3. Group TNIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
4. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123:750-8.
5. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003;9:1313-7.
6. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7:59-64.
7. Goto H, Fujisawa H, Oka F, Nomura S, Kajiwara K, Kato S, et al. Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain. J Neurotrauma. 2007;24:745-52.
8. Di Napoli M, Shah IM. Neuroinflammation and cerebrovascular disease in old age: A translational medicine perspective. J Aging Res. 2011;2011:857484.
9. Moskowitz MA. Brain protection: maybe yes, maybe no. Stroke. 2010;41:S85-6.
10. del Zoppo GJ. Acute anti-inflammatory approaches to ischemic stroke. Ann N Y Acad Sci. 2010;1207:143-8.
11. Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci. 2011;14:1363-8.
12. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke. 2006;37:2181-8.
13. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP pooling project members. Stroke. 2005;36:1316-29.
14. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-25.
15. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
16. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation. 2005;112:1813-24.
17. Liu H, Zhang J. Cerebral hypoperfusion and cognitive impairment: The pathogenic role of vascular oxidative stress. Int J Neurosci. 2012;122:494-9.
18. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173-85.
19. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010;120:287-96.
20. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347-60.
21. Langdon KD, Maclellan CL, Corbett D. Prolonged, 24-h delayed peripheral inflammation increases short-and long-term functional impairment and histopathological damage after focal ischemia in the rat. J Cereb Blood Flow Metab. 2010;30:1450-9.
22. Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke. 2009;40:1262-8.
23. Denes A, Humphreys N, Lane TE, Grencis R, Rothwell N. Chronic systemic infection exacerbates ischemic brain damage via a ccl5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. J Neurosci. 2010;30:10086-95.
24. Dhungana H, Malm T, Denes A, Valonen P, Wojciechowski S, Magga J, et al. Aging aggravates ischemic stroke-induced brain damage in mice with chronic peripheral infection. Aging Cell. 2013;12:842-50.
25. Gresa-Arribas N, Vieitez C, Dentesano G, Serratosa J, Saura J, Sola C. Modelling neuroinflammation in vitro: A tool to test the potential neuroprotective effect of anti-inflammatory agents. PLoS One. 2012;7:e45227.
26. Denes A, Ferenczi S, Kovacs KJ. Systemic inflammatory challenges compromise survival after experimental stroke via augmenting brain inflammation, blood-brain barrier damage and brain oedema independently of infarct size. J Neuroinflammation. 2011;8:164.
27. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-8.
28. Vermeij FH, Scholte op Reimer WJ, de Man P, van Oostenbrugge RJ, Franke CL, de Jong G, et al. Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands stroke survey. Cerebrovasc Dis. 2009;27: 465-71.
29. Salat D, Penalba A, Garcia-Berrocoso T, Campos-Martorell M, Flores A, Pagola J, et al. Immunological biomarkers improve the accuracy of clinical risk models of infection in the acute phase of ischemic stroke. Cerebrovasc Dis. 2013;35:220-7.
30. Smith CJ, Tyrrell PJ. Current and emerging treatments for acute stroke: relationships with infection. Infect Disord Drug Targets. 2010;10:112-21.
31. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010;6:681-94.
32. Benjamin LA, Bryer A, Emsley HC, Khoo S, Solomon T, Connor MD. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11:878-90.
33. Elkind MS. Infectious burden: A new risk factor and treatment target for atherosclerosis. Infect Disord Drug Targets. 2010;10:84-90.
34. Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, et al. Infectious burden and risk of stroke: The Northern Manhattan study. Arch Neurol. 2010;67:33-8.
35. Elkind MS, Carty CL, O'Meara ES, Lumley T, Lefkowitz D, Kronmal RA, et al. Hospitalization for infection and risk of acute ischemic stroke: The cardiovascular health study. Stroke. 2011;42:1851-6.
36. Elkind MS, Cole JW. Do common infections cause stroke? Semin Neurol. 2006;26:88-99.
37. Elkind MS. Why now? Moving from stroke risk factors to stroke triggers. Curr Opin Neurol. 2007;20:51-7.
38. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis. 2009;27:247-53.
39. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-7.
40. Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology. 2009;56:329-41.
41. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-98.
42. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
43. Shichita T, Sakaguchi R, Suzuki M, Yoshimura A. Post-ischemic inflammation in the brain. Front Immunol. 2012;3:132.
44. del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879-94.
45. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000;190:255-66.
46. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656-65.
47. Franks ZG, Campbell RA, Weyrich AS, Rondina MT. Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci. 2010; 1207:11-7.
48. Ishikawa M, Zhang JH, Nanda A, Granger DN. Inflammatory responses to ischemia and reperfusion in the cerebral microcirculation. Front Biosci. 2004;9:1339-47.
49. Atochin DN, Wang A, Liu VW, Critchlow JD, Dantas AP, Looft-Wilson R, et al. The phosphorylation state of ENOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest. 2007;117:1961-7.
50. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke. 1991;22:1276-83.
51. Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol. 1999;98:77-88.
52. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury. Neuromolecular Med. 2010;12:193-204.
53. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69:576-81.
54. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinalfluid barriers: function and dysfunction. Semin Immunopathol. 2009;31:497-511.
55. Lindsberg PJ, Strbian D, Karjalainen-Lindsberg ML. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab. 2010;30:689-702.
56. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab. 2006;26:605-12.
57. Konsman JP, Drukarch B, VanDam AM. Perivascular production and action of proinflammatory cytokines in brain pathology. Clin Sci (Lond). 2007;112:1-25.
58. Sairanen TR, Lindsberg PJ, Brenner M, Siren AL. Global forebrain ischemia results in differential cellular expression of interleukin-1beta (IL-1beta) and its receptor at mRNA and protein level. J Cereb Blood Flow Metab. 1997;17:1107-20.
59. Schilling M, Strecker JK, Ringelstein EB, Kiefer R, Schabitz WR. Turn-over of meningeal and perivascular macrophages in the brain of MCP-1-, CCR-2-or double knockout mice. Exp Neurol. 2009;219:583-5.
60. Terao S, Yilmaz G, Stokes KY, Russell J, Ishikawa M, Kawase T, et al. Blood cell-derived rantes mediates cerebral microvascular dysfunction, inflammation, and tissue injury after focal ischemia-reperfusion. Stroke. 2008;39:2560-70.
61. Bune LT, Thaning P, Johansson PI, Bochsen L, Rosenmeier JB. Effects of nucleotides and nucleosides on coagulation. Blood Coagul Fibrinolysis. 2010;21:436-41.
62. Melani A, Turchi D, Vannucchi MG, Cipriani S, Gianfriddo M, Pedata F. ATP extracellular concentrations are increased in the rat striatum during in vivo ischemia. Neurochem Int. 2005;47:442-8.
63. Schock SC, Munyao N, Yakubchyk Y, Sabourin LA, Hakim AM, Ventureyra EC, et al. Cortical spreading depression releases ATP into the extracellular space and purinergic receptor activation contributes to the induction of ischemic tolerance. Brain Res. 2007;1168: 129-38.
64. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7:575-90.
65. Pocock JM, Kettenmann H. Neurotransmitter receptors on microglia. Trends Neurosci. 2007;30:527-35.
66. Peachell P. Regulation of mast cells by beta-agonists. Clin Rev Allergy Immunol. 2006; 31:131-42.
67. Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol. 2003;170:4953-62.
68. Sparkman NL, Johnson RW. Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. Neuroimmunomodulation. 2008;15:323-30.
69. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8:279-89.
70. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112:358-404.
71. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience. 2009;158:1007-20.
72. Jurgens HA, Johnson RW. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation. Exp Neurol. 2012;233:40-8.
73. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci. 2000;20:RC87.
74. Orellana JA, Froger N, Ezan P, Jiang JX, Bennett MV, Naus CC, et al. ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels. J Neurochem. 2011;118:826-40.
75. Li F, Wang L, Li JW, Gong M, He L, Feng R, et al. Hypoxia induced amoeboid microglial cell activation in postnatal rat brain is mediated by ATP receptor p2x4. BMC Neurosci. 2011;12:111.
76. Zhang J, Takahashi HK, Liu K, Wake H, Liu R, Maruo T, et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke. 2011;42:1420-8.
77. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, et al. Hmbg1 mediates ischemiareperfusion injury by TRIF-adaptor independent toll-like receptor 4 signaling. J Cereb Blood Flow Metab. 2011;31:593-605.
78. Yang QW, Wang JZ, Li JC, Zhou Y, Zhong Q, Lu FL, et al. High-mobility group protein box-1 and its relevance to cerebral ischemia. J Cereb Blood Flow Metab. 2010;30:243-54.
79. Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. Hmgb1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol. 2013;55:76-82.
80. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, et al. Downregulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290:1768-71.
81. Matsumoto H, Kumon Y, Watanabe H, Ohnishi T, Takahashi H, Imai Y, et al. Expression of CD200 by macrophage-like cells in ischemic core of rat brain after transient middle cerebral artery occlusion. Neurosci Lett. 2007;418:44-8.
82. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of cx3cr1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab. 2008;28:1707-21.
83. Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, et al. Cx3cl1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci. 2011;31:16327-35.
84. Fumagalli S, Perego C, Ortolano F, De Simoni MG. Cx3cr1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia. 2013;61:827-42.
85. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol. 2009;68: 217-26.
86. Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med. 2012;18:911-7.
87. Mallard C. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol. 2012;2012:701950.
88. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314-8.
89. Lassmann H, Schmied M, Vass K, Hickey WF. Bone marrow derived elements and resident microglia in brain inflammation. Glia. 1993;7:19-24.
90. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841-5.
91. Bechmann I, Priller J, Kovac A, Bontert M, Wehner T, Klett FF, et al. Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur J Neurosci. 2001;14: 1651-8.
92. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23:344-6.
93. Rao KN, Brown MA. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann N Y Acad Sci. 2008;1143:83-104.
94. Tanaka R, Komine-Kobayashi M, Mochizuki H, Yamada M, Furuya T, Migita M, et al. Migration of enhanced greenfluorescent protein expressing bone marrow-derived microglia/ macrophage into the mouse brain following permanent focal ischemia. Neuroscience. 2003;117:531-9.
95. Felger JC, Abe T, Kaunzner UW, Gottfried-Blackmore A, Gal-Toth J, McEwen BS, et al. Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav Immun. 2010;24:724-37.
96. Reichmann G, Schroeter M, Jander S, Fischer HG. Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J Neuroimmunol. 2002;129:125-32.
97. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010;33:657-70.
98. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849-57.
99. Yilmaz A, Fuchs T, Dietel B, Altendorf R, Cicha I, Stumpf C, et al. Transient decrease in circulating dendritic cell precursors after acute stroke: potential recruitment into the brain. Clin Sci (Lond). 2010;118:147-57.
100. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellularfluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992;2:269-76.
101. Becker KJ, McCarron RM, Ruetzler C, Laban O, Sternberg E, Flanders KC, et al. Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A. 1997;94:10873-8.
102. Becker KJ. Sensitization and tolerization to brain antigens in stroke. Neuroscience. 2009;158:1090-7.
103. Becker K, Kindrick D, McCarron R, Hallenbeck J, Winn R. Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: A role for lymphocytes in ischemic brain injury? Stroke. 2003;34:1809-15.
104. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, Weiner HL. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci. 2005;233:125-32.
105. Subramanian S, Zhang B, Kosaka Y, Burrows GG, Grafe MR, Vandenbark AA, et al. Recombinant T cell receptor ligand treats experimental stroke. Stroke. 2009;40:2539-45.
106. Hurn PD, Subramanian S, Parker SM, Afentoulis ME, Kaler LJ, Vandenbark AA, et al. T-and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab. 2007;27:1798-805.
107. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835-42.
108. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammadeltat cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946-50.
109. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15:192-9.
110. Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. Cd4+foxp3+ regulatory T-cells in cerebral ischemic stroke. Metab Brain Dis. 2011;26:87-90.
111. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferongamma in ischemic stroke. Circulation. 2006;113:2105-12.
112. Sandhir R, Onyszchuk G, Berman NE. Exacerbated glial response in the aged mouse hippocampus following controlled cortical impact injury. Exp Neurol. 2008;213:372-80.
113. Godbout JP, Johnson RW. Age and neuroinflammation: A lifetime of psychoneuroimmune consequences. Immunol Allergy Clin North Am. 2009;29:321-37.
114. Tanaka Y, Matsuwaki T, Yamanouchi K, Nishihara M. Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. Neuroscience. 2013;231:49-60.
115. Badan I, Buchhold B, Hamm A, Gratz M, Walker LC, Platt D, et al. Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J Cereb Blood Flow Metab. 2003;23:845-54.
116. Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Grimmig B, Diamond D, et al. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PLoS One. 2013;8:e53376.
117. Wasserman JK, Yang H, Schlichter LC. Glial responses, neuron death and lesion resolution after intracerebral hemorrhage in young vs. aged rats. Eur J Neurosci. 2008;28:1316-28.
118. Hasegawa-Ishii S, Takei S, Inaba M, Umegaki H, Chiba Y, Furukawa A, et al. Defects in cytokine-mediated neuroprotective glial responses to excitotoxic hippocampal injury in senescence-accelerated mouse. Brain Behav Immun. 2011;25:83-100.
119. Lee JC, Cho GS, Choi BO, Kim HC, Kim WK. Aging exacerbates intracerebral hemorrhageinduced brain injury. J Neurotrauma. 2009;26:1567-76.
120. Akbik FV, Bhagat SM, Patel PR, Cafferty WB, Strittmatter SM. Anatomical plasticity of adult brain is titrated by Nogo receptor 1. Neuron. 2013;77:859-66.
121. Kempf A, Montani L, Petrinovic MM, Schroeter A, Weinmann O, Patrignani A, et al. Upregulation of axon guidance molecules in the adult central nervous system of Nogo-A knockout mice restricts neuronal growth and regeneration. Eur J Neurosci. 2013;38: 3567-79.
122. Streit WJ, Miller KR, Lopes KO, Njie E. Microglial degeneration in the aging brain-bad news for neurons? Front Biosci. 2008;13:3423-38.
123. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288-95.
124. Wong WT. Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Front Cell Neurosci. 2013;7:22.
125. Kotter MR, Li WW, Zhao C, Franklin RJ. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci. 2006;26:328-32.
126. Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron. 2005;48:9-12.
127. Clarner T, Diederichs F, Berger K, Denecke B, Gan L, van der Valk P, et al. Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia. 2012;60:1468-80.
128. Kang H, Lichtman JW. Motor axon regeneration and muscle reinnervation in young adult and aged animals. J Neurosci. 2013;33:19480-91.
129. Chari DM, Zhao C, Kotter MR, Blakemore WF, Franklin RJ. Corticosteroids delay remyelination of experimental demyelination in the rodent central nervous system. J Neurosci Res. 2006;83:594-605.
130. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013;16:1211-8.
131. Guadagno J, Xu X, Karajgikar M, Brown A, Cregan SP. Microglia-derived TNFalpha induces apoptosis in neural precursor cells via transcriptional activation of the bcl-2 family member puma. Cell Death Dis. 2013;4:e538.
132. Di Napoli M, Elkind MS, Godoy DA, Singh P, Papa F, Popa-Wagner A. Role of C-reactive protein in cerebrovascular disease: A critical review. Expert Rev Cardiovasc Ther. 2011;9: 1565-84.
133. Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol. 2003;139:93-101.
134. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in thefirst week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4:2.
135. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: A systematic review. Stroke. 2009;40:e380-9.
136. Montaner J, Fernandez-Cadenas I, Molina CA, Ribo M, Huertas R, Rosell A, et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke. 2006;37:1205-10.
137. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke. 2005;36:2143-7.
138. Arenillas JF, Alvarez-Sabin J, Molina CA, Chacon P, Montaner J, Rovira A, et al. C-Reactive protein predicts further ischemic events infirst-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003;34:2463-8.
139. Di Napoli M, Papa F, Bocola V. C-Reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917-24.
140. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-Reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-5.
141. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements afterfirst ischemic stroke. Stroke. 2002;33:2459-64.
142. Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, Ladenvall P. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke. 2006;37:2018-23.
143. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab. 2004;24:1214-8.
144. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440: 1217-21.
145. Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol. 2008;7:341-53.
146. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke. 2007;38:770-3.
147. Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: A manifestation of brain-induced immunodepression. Stroke. 2007;38:1097-103.
148. Haeusler KG, Schmidt WU, Fohring F, Meisel C, Helms T, Jungehulsing GJ, et al. Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis. 2008;25:50-8.
149. Sarrafzadeh A, Schlenk F, Meisel A, Dreier J, Vajkoczy P, Meisel C. Immunodepression after aneurysmal subarachnoid hemorrhage. Stroke. 2011;42:53-8.
150. Sykora M, Diedler J, Poli S, Rizos T, Turcani P, Veltkamp R, et al. Autonomic shift and increased susceptibility to infections after acute intracerebral hemorrhage. Stroke. 2011;42: 1218-23.
151. Chamorro A, Amaro S, Vargas M, Obach V, Cervera A, Torres F, et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry. 2006;77:1279-81.
152. Tanzi P, Cain K, Kalil A, Zierath D, Savos A, Gee JM, et al. Post-stroke infection: A role for IL-1ra? Neurocrit Care. 2011;14:244-52.
153. Urra X, Villamor N, Amaro S, Gomez-Choco M, Obach V, Oleaga L, et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab. 2009;29:994-1002.
154. Yan J, Greer JM, Etherington K, Cadigan GP, Cavanagh H, Henderson RD, et al. Immune activation in the peripheral blood of patients with acute ischemic stroke. J Neuroimmunol. 2009;206:112-7.
155. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood. 2013;121:679-91.
156. Emsley HC, Smith CJ, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol. 2007;7:5.
157. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodefi-ciency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198: 725-36.
158. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci. 2005;6:775-86.
159. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, et al. Monitoring temporary immunodepression byflow cytometric measurement of monocytic HLA-DR expression: A multicenter standardized study. Clin Chem. 2005;51:2341-7.
160. Offner H, Vandenbark AA, Hurn PD. Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression. Neuroscience. 2009;158:1098-111.
161. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033-6.
162. Oprica M, Eriksson C, Schultzberg M. Inflammatory mechanisms associated with brain damage induced by kainic acid with special reference to the interleukin-1 system. J Cell Mol Med. 2003;7:127-40.
163. Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009;9:418-28.
164. Smith CJ, Emsley HC, Udeh CT, Vail A, Hoadley ME, Rothwell NJ, et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine. 2012;58:384-9.
165. Turnbull AV, Prehar S, Kennedy AR, Little RA, Hopkins SJ. Interleukin-6 is an afferent signal to the hypothalamo-pituitary-adrenal axis during local inflammation in mice. Endocrinology. 2003;144:1894-906.
166. Kox M, Vrouwenvelder MQ, Pompe JC, van der Hoeven JG, Pickkers P, Hoedemaekers CW. The effects of brain injury on heart rate variability and the innate immune response in critically ill patients. J Neurotrauma. 2012;29:747-55.
167. Walter U, Kolbaske S, Patejdl R, Steinhagen V, Abu-Mugheisib M, Grossmann A, et al. Insular stroke is associated with acute sympathetic hyperactivation and immunodepression. Eur J Neurol. 2013;20:153-9.
168. Hetze S, Engel O, Romer C, Mueller S, Dirnagl U, Meisel C, et al. Superiority of preventive antibiotic treatment compared with standard treatment of poststroke pneumonia in experimental stroke: A bed to bench approach. J Cereb Blood Flow Metab. 2013;33:846-54.
169. van de Beek D, Wijdicks EF, Vermeij FH, de Haan RJ, Prins JM, Spanjaard L, et al. Preventive antibiotics for infections in acute stroke: A systematic review and meta-analysis. Arch Neurol. 2009;66:1076-81.
170. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007;69:1404-10.
171. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy. 2006;26:515-21.
172. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51:333-55.
173. Peeters BW, Tonnaer JA, Groen MB, Broekkamp CL, van der Voort HA, Schoonen WG, et al. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress. 2004;7:233-41.
174. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441-5.
175. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170-84.
176. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140:871-82.
177. Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med. 2010;207:1807-17.
178. Rappert A, Bechmann I, Pivneva T, Mahlo J, Biber K, Nolte C, et al. Cxcr3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci. 2004;24:8500-9.
179. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752-8.
180. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology. 2006;117:433-42.
181. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8:221-32.
182. Greenberg DA, Jin K. Growth factors and stroke. NeuroRx. 2006;3:458-65.
183. Carmichael ST. Translating the frontiers of brain repair to treatments: starting not to break the rules. Neurobiol Dis. 2010;37:237-42.
184. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res. 2002;90:284-8.
185. Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci. 2007;27: 2596-605.
186. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, et al. Correlation of vegf and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab. 2002;22:379-92.
187. Hao Q, Chen Y, Zhu Y, Fan Y, Palmer D, Su H, et al. Neutrophil depletion decreases vegfinduced focal angiogenesis in the mature mouse brain. J Cereb Blood Flow Metab. 2007;27:1853-60.
188. Manoonkitiwongsa PS, Schultz RL, McCreery DB, Whitter EF, Lyden PD. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J Cereb Blood Flow Metab. 2004;24: 693-702.
189. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. Vegf enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000; 106:829-38.
190. Li S, Overman JJ, Katsman D, Kozlov SV, Donnelly CJ, Twiss JL, et al. An age-related sprouting transcriptome provides molecular control of axonal sprouting after stroke. Nat Neurosci. 2010;13:1496-504.
191. Popa-Wagner A, Buga AM, Kokaia Z. Perturbed cellular response to brain injury during aging. Ageing Res Rev. 2011;10:71-9.
192. Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol. 2005;4:752-9.
193. Jantaratnotai N, Ryu JK, Schwab C, McGeer PL, McLarnon JG. Comparison of vascular perturbations in an abeta-injected animal model and in AD brain. Int J Alzheimers Dis. 2011;2011:918280.
194. Grammas P, Sanchez A, Tripathy D, Luo E, Martinez J. Vascular signaling abnormalities in Alzheimer disease. Cleve Clin J Med. 2011;78 Suppl 1:S50-3.
195. Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One. 2011;6:e23789.
196. Wallin A, Ohrfelt A, Bjerke M. Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. J Neurol Sci. 2012;322:192-6.
197. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology. 2012;78: 167-74.
198. Whitehead SN, Massoni E, Cheng G, Hachinski VC, Cimino M, Balduini W, et al. Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer's disease and stroke. Brain Res. 2010;1366:246-56.
199. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1-and neutrophil-dependent mechanisms. J Neurosci. 2007;27:4403-12.
200. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC. Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab. 2005;25:1634-44.
201. Zierath D, Thullbery M, Hadwin J, Gee JM, Savos A, Kalil A, et al. CNS immune responses following experimental stroke. Neurocrit Care. 2010;12:274-84.
202. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11:1753-63.
203. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507-12.
204. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40:e50-2.
205. Smith CJ, Lawrence CB, Rodriguez-Grande B, Kovacs KJ, Pradillo JM, Denes A. The immune system in stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol. 2013;8(4):867-87.
206. Arumugam TV, Selvaraj PK, Woodruff TM, Mattson MP. Targeting ischemic brain injury with intravenous immunoglobulin. Expert Opin Ther Targets. 2008;12:19-29.
207. Investigators EAST. Use of anti-icam-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology. 2001;57:1428-34.
208. Furuya K, Takeda H, Azhar S, McCarron RM, Chen Y, Ruetzler CA, et al. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: A bedside-to-bench study. Stroke. 2001;32:2665-74.
209. Pradillo JM, Denes A, Greenhalgh AD, Boutin H, Drake C, McColl BW, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab. 2012;32:1810-9.
210. Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76:1366-72.
211. Gueorguieva I, Clark SR, McMahon CJ, Scarth S, Rothwell NJ, Tyrrell PJ, et al. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinalfluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol. 2008;65:317-25.
212. Kohler E, Prentice DA, Bates TR, Hankey GJ, Claxton A, van Heerden J, et al. Intravenous minocycline in acute stroke: A randomized, controlled pilot study and meta-analysis. Stroke. 2013;44:2493-9.
213. Hess DC, Hoda MN, Bhatia K. Remote limb preconditioning and postconditioning: will it translate into a promising treatment for acute stroke? Stroke. 2013;44:1191-7.
214. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci. 2006;7:437-48.
215. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab. 2002;22:1283-96.
216. Stenzel-Poore MP, Stevens SL, Simon RP. Genomics of preconditioning. Stroke. 2004;35:2683-6.
217. Bordet R, Deplanque D, Maboudou P, Puisieux F, Pu Q, Robin E, et al. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab. 2000;20:1190-6.
218. Petcu EB, Kocher T, Kuhr A, Buga AM, Kloting I, Herndon JG, et al. Mild systemic inflammation has a neuroprotective effect after stroke in rats. Curr Neurovasc Res. 2008;5: 214-23.
219. Kariko K, Weissman D, Welsh FA. Inhibition of toll-like receptor and cytokine signaling-A unifying theme in ischemic tolerance. J Cereb Blood Flow Metab. 2004;24:1288-304.
220. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, et al. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: A critical role for IRF3. J Neurosci. 2009;29:9839-49.
221. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factorkappaB is a key event in brain tolerance. J Neurosci. 2001;21:4668-77.
222. Kunz A, Park L, Abe T, Gallo EF, Anrather J, Zhou P, et al. Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci. 2007;27:7083-93.
223. Ohtsuki T, Ruetzler CA, Tasaki K, Hallenbeck JM. Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal ca1 neurons. J Cereb Blood Flow Metab. 1996;16:1137-42.
224. Pradillo JM, Romera C, Hurtado O, Cardenas A, Moro MA, Leza JC, et al. TNFr1 upregulation mediates tolerance after brain ischemic preconditioning. J Cereb Blood Flow Metab. 2005;25:193-203.
225. Ziv Y, Finkelstein A, Geffen Y, Kipnis J, Smirnov I, Shpilman S, et al. A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis. Stroke. 2007;38: 774-82.
226. Steinman L. A brief history of t(h)17, thefirst major revision in the t(h)1/t(h)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139-45.
227. Schwartz M, London A, Shechter R. Boosting T-cell immunity as a therapeutic approach for neurodegenerative conditions: The role of innate immunity. Neuroscience. 2009;158: 1133-42.
228. Kuo JR, Lo CJ, Chang CP, Lin HJ, Lin MT, Chio CC. Brain cooling-stimulated angiogenesis and neurogenesis attenuated traumatic brain injury in rats. J Trauma. 2010;69:1467-72.
229. Schwartz AE, Finck AD, Stone JG, Connolly ES, Edwards NM, Mongero L. Delayed selective cerebral hypothermia decreases infarct volume after reperfused stroke in baboons. J Neurosurg Anesthesiol. 2011;23:124-30.
230. Miyazawa T, Tamura A, Fukui S, Hossmann KA. Effect of mild hypothermia on focal cerebral ischemia. Review of experimental studies. Neurol Res. 2003;25:457-64.
231. Luan X, Li J, McAllister 2nd JP, Diaz FG, Clark JC, Fessler RD, et al. Regional brain cooling induced by vascular saline infusion into ischemic territory reduces brain inflammation in stroke. Acta Neuropathol. 2004;107:227-34.
232. Kollmar R, Blank T, Han JL, Georgiadis D, Schwab S. Different degrees of hypothermia after experimental stroke: short-and long-term outcome. Stroke. 2007;38:1585-9.
233. Kollmar R, Schwab S. Hypothermia and ischemic stroke. Curr Treat Options Neurol. 2012;83(10):1252-9.
234. Florian B, Vintilescu R, Balseanu AT, Buga AM, Grisk O, Walker LC, et al. Long-term hypothermia reduces infarct volume in aged rats after focal ischemia. Neurosci Lett. 2008;438: 180-5.
235. Joseph C, Buga AM, Vintilescu R, Balseanu AT, Moldovan M, Junker H, et al. Prolonged gaseous hypothermia prevents the upregulation of phagocytosis-specific protein annexin 1 and causes low-amplitude EEG activity in the aged rat brain after cerebral ischemia. J Cereb Blood Flow Metab. 2012;32:1632-42.
236. Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell. 2004;117:561-74.
237. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6:813-22.
238. Liu W, Hendren J, Qin XJ, Liu KJ. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia. Stroke. 2009;40:2526-31.
239. Patel DM, Ahmad SF, Weiss DG, Gerke V, Kuznetsov SA. Annexin a1 is a new functional linker between actinfilaments and phagosomes during phagocytosis. J Cell Sci. 2011;124: 578-88.
240. Popa-Wagner A, Stocker K, Balseanu AT, Rogalewski A, Diederich K, Minnerup J, et al. Effects of granulocyte-colony stimulating factor after stroke in aged rats. Stroke. 2010;41: 1027-31.
241. Oliani SM, Paul-Clark MJ, Christian HC, Flower RJ, Perretti M. Neutrophil interaction with inflamed postcapillary venule endothelium alters annexin 1 expression. Am J Pathol. 2001;158:603-15.
242. Bouma HR, Carey HV, Kroese FG. Hibernation: The immune system at rest? J Leukoc Biol. 2010;88:619-24.
243. Seo JW, Kim JH, Seo M, Han HS, Park J, Suk K. Time-dependent effects of hypothermia on microglial activation and migration. J Neuroinflammation. 2012;9:164.
244. Liu L, Yenari MA. Clinical application of therapeutic hypothermia in stroke. Neurol Res. 2009;31:331-5.
245. Drabek T, Kochanek PM, Stezoski J, Wu X, Bayir H, Morhard RC, et al. Intravenous hydrogen sulfide does not induce hypothermia or improve survival from hemorrhagic shock in pigs. Shock. 2011;35:67-73.
246. Bi M, Ma Q, Zhang S, Li J, Zhang Y, Lin L, et al. Local mild hypothermia with thrombolysis for acute ischemic stroke within a 6-h window. Clin Neurol Neurosurg. 2011;113:768-73.
247. Shi S, Wang Z, Qiao Z. The multifunctional anti-inflammatory drugs used in the therapy of Alzheimer's disease. Curr Med Chem. 2013;20:2583-8.
248. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal antiinflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2012;2, CD006378.
249. Baud L, Fouqueray B, Bellocq A, Peltier J. [calpains participate in inflammatory reaction development]. Med Sci (Paris). 2003;19:71-6.
250. Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, et al. Calpain inhibitor a-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xtgad mice. Am J Pathol. 2012;181:616-25.
251. Lee YJ, Choi DY, Yun YP, Han SB, Oh KW, Hong JT. Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its antineuroinflammatory properties. J Nutr Biochem. 2013;24:298-310.
252. Fan T, Jiang WL, Zhu J, Feng ZY. Arctigenin protects focal cerebral ischemia-reperfusion rats through inhibiting neuroinflammation. Biol Pharm Bull. 2012;35:2004-9.
253. Shindo T, Takasaki K, Uchida K, Onimura R, Kubota K, Uchida N, et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull. 2012;35:2141-7.
254. Rabinovich-Nikitin I, Rakover IS, Becker M, Solomon B. Beneficial effect of antibodies against beta-secretase cleavage site of app on Alzheimer's-like pathology in triple-transgenic mice. PLoS One. 2012;7:e46650.